Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

511
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
511
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

207
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
207
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

853
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
853
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

543
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
543
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

283
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
283

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clomipramine-Induced Urinary Retention in an Adult Male - A Case Report.

Current drug safety·2025
Same author

Oral Linezolid Induced Early Onset Hepatic Encephalopathy- A Case Report of 65-year Old Diabetic Female.

Current drug safety·2023
Same author

Cochlear Implants: Evaluation of Effects of Various Parameters on Outcomes in Pediatric Patients at a Tertiary Care Centre for Unilateral Ear Implantation.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India·2022
Same author

Comparison of safety and analgesic efficacy of diclofenac sodium with etodolac after surgical extraction of third molars: a randomized, double-blind, double-dummy, parallel-group study.

Journal of dental anesthesia and pain medicine·2020
Same author

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report.

Drug safety - case reports·2018
Same author

Tramadol-Induced Hiccups: A Report of Two Cases.

Drug safety - case reports·2018

Related Experiment Video

Updated: Jan 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.6K

Isoniazid-Induced Systemic Lupus Erythematosus: A Case Report.

Jitendra H Vaghela1, Yogesh Solanki2, Krishna Lakhani2

  • 1Department of Pharmacology, Government Medical College, Bhavnagar, Gujarat, 364001, India. drjitendravaghela@gmail.com.

Drug Safety - Case Reports
|September 22, 2019
PubMed
Summary

Isoniazid, a tuberculosis drug, can trigger drug-induced systemic lupus erythematosus (SLE). Stopping isoniazid improved the patient's condition, confirming its probable role in causing SLE.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

879
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.8K

Related Experiment Videos

Last Updated: Jan 19, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.6K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

879
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.8K

Area of Science:

  • Pharmacology
  • Immunology
  • Infectious Diseases

Background:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease with various known drug-induced causes.
  • Tuberculosis treatment regimens may include medications with potential side effects.
  • Drug-induced SLE presents a diagnostic challenge, especially when overlapping symptoms occur.

Purpose of the Study:

  • To report a case of drug-induced systemic lupus erythematosus (SLE) potentially caused by isoniazid.
  • To highlight the diagnostic considerations for SLE in patients undergoing tuberculosis treatment.
  • To assess the causality of isoniazid in the development of SLE.

Main Methods:

  • A patient diagnosed with tuberculous meningitis received antituberculosis treatment.
  • Clinical presentation, laboratory investigations (including antinuclear antibody levels), and drug history were reviewed.
  • Causality assessment was performed using WHO-UMC and Naranjo's criteria.
  • Severity was graded using the modified Hartwig and Siegel scale.

Main Results:

  • The patient developed symptoms suggestive of SLE despite antituberculosis treatment.
  • Elevated antinuclear antibody levels confirmed autoimmune activity.
  • Discontinuation of isoniazid led to significant clinical improvement.
  • Isoniazid was identified as the probable causative agent for drug-induced SLE (WHO-UMC and Naranjo's criteria).
  • The reaction was classified as moderately severe (level 4b).

Conclusions:

  • Isoniazid can induce systemic lupus erythematosus (SLE).
  • Early recognition and withdrawal of the offending drug are crucial for patient recovery.
  • This case underscores the importance of considering drug-induced SLE in patients with unexplained autoimmune symptoms during medication therapy.